Bernard Roizman, the virologist whose groundbreaking research on herpes simplex virus transformed our understanding of how pathogens invade human cells, died at 96. His work established the molecular foundation for modern antiviral treatments and opened pathways toward herpes vaccines and gene therapies.
Roizman's most consequential achievement was mapping the herpes simplex virus genome. By sequencing and analyzing the virus's genetic structure, he revealed the precise mechanisms by which herpes infiltrates cells and replicates inside them. This wasn't abstract science. Understanding these invasion pathways directly enabled the development of drugs like acyclovir, which blocks viral replication by targeting specific enzymes the virus depends on.
His research extended beyond treatment to prevention. By clarifying how herpes proteins interact with host cells, Roizman identified potential vaccine targets. Researchers studying herpes vaccines today still reference his foundational work on viral glycoproteins, the spike-like structures that allow the virus to dock onto cells.
Gene therapy applications also emerged from his discoveries. Because Roizman had mapped exactly which herpes genes controlled infection, scientists could design modified herpes vectors as delivery systems for therapeutic genes. These engineered viruses now serve as tools in cancer immunotherapy and neurological disease research.
Roizman worked primarily at the University of Chicago, where he established one of the world's premier herpesvirus research centers. His peers credited him with elevating virology from description to mechanism, from observing what viruses did to explaining precisely how they did it.
The herpes simplex virus remains one of the most common human pathogens, infecting roughly two-thirds of the global population under age 50. While Roizman's work gave us acyclovir and related antivirals that suppress symptoms, a vaccine remains elusive despite decades of effort. His legacy includes not